[中国冠心病二级预防研究（CCSPS）：冠心病合并糖尿病患者的分析结果]

[China coronary secondary prevention study (CCSPS): outcomes from analysis of coronary heart disease patients with diabetes].

作者信息

Lu Zong-liang, Du Bao-min, Chen Zuo, Wu Yang-feng, Yu Xue-hai, Zhao Yu-chen

机构信息

Cardiovascular Institute and Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.

出版信息

Zhonghua Xin Xue Guan Bing Za Zhi. 2005 Dec;33(12):1067-70.

PMID:16563271

Abstract

OBJECTIVE

To elucidate whether lipid-lowering therapy with Xuezhikang can induce a decrease of cardiac events and an attenuation of total mortality in coronary heart disease (CHD) patients with diabetes.

METHODS

We designed a random, double-blinded, placebo controlled clinical trial in selected 591 patients. All patients were administrated with capsule Xuezhikang (0.6 g, Bid) or placebo in addition to conventional therapy. The mean follow-up period was four years. The primary end-points were nonfatal myocardial infarction and death from CHD.

RESULTS

(1) The incidence of CHD events and that of death from CHD were reduced by 50.8% (P = 0.0008) and by 44.1% (P = 0.0246) in treatment group, respectively; Also, the incidence of nonfatal myocardial infarction was reduced by 63.8% (P = 0.0151). (2) The incidence of stroke, tumor, and PCI/CABG were decreased by 20.2%. (3) The total mortality were lowered by 44.1% in treatment group (P = 0.0097).

CONCLUSION

Xuezhikang can effectively reduce the incidence of cardiac events and total mortality in CHD patients with diabetes.

摘要

目的

阐明血脂康降脂治疗能否降低糖尿病冠心病（CHD）患者的心脏事件发生率及总死亡率。

方法

我们设计了一项随机、双盲、安慰剂对照的临床试验，选取591例患者。所有患者在接受常规治疗的基础上，服用血脂康胶囊（0.6 g，每日2次）或安慰剂。平均随访期为4年。主要终点为非致死性心肌梗死和CHD死亡。

结果

（1）治疗组CHD事件发生率和CHD死亡率分别降低了50.8%（P = 0.0008）和44.1%（P = 0.0246）；此外，非致死性心肌梗死发生率降低了63.8%（P = 0.0151）。（2）中风、肿瘤及PCI/CABG的发生率降低了20.2%。（3）治疗组总死亡率降低了44.1%（P = 0.0097）。